

Pedro M Rodriguez Cruz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/199167/publications.pdf>

Version: 2024-02-01

32
papers

1,148
citations

361413

20
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

1353
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. <i>JAMA Neurology</i> , 2015, 72, 642.	9.0	118
2	Mutations in <i>GMPPB</i> cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. <i>Brain</i> , 2015, 138, 2493-2504.	7.6	111
3	The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 610964.	2.9	83
4	The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1677.	4.1	77
5	Congenital myasthenic syndromes and the neuromuscular junction. <i>Current Opinion in Neurology</i> , 2014, 27, 566-575.	3.6	57
6	Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in <i>COL13A1</i> , Encoding the Atypical Non-fibrillar Collagen Type XIII $\beta 1$ Chain. <i>American Journal of Human Genetics</i> , 2015, 97, 878-885.	6.2	57
7	An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. <i>Neuromuscular Disorders</i> , 2014, 24, 1025-1035.	0.6	55
8	Clinical features of the myasthenic syndrome arising from mutations in <i>GMPPB</i> . <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 802-809.	1.9	55
9	Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. <i>Experimental Neurology</i> , 2015, 270, 66-71.	4.1	54
10	Molecular characterization of congenital myasthenic syndromes in Spain. <i>Neuromuscular Disorders</i> , 2017, 27, 1087-1098.	0.6	51
11	Serological and experimental studies in different forms of myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 143-153.	3.8	44
12	Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. <i>Neurology</i> , 2015, 85, 1043-1047.	1.1	43
13	Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature. <i>Neuromuscular Disorders</i> , 2014, 24, 1103-1110.	0.6	41
14	Inherited disorders of the neuromuscular junction: an update. <i>Journal of Neurology</i> , 2014, 261, 2234-2243.	3.6	32
15	The clinical spectrum of the congenital myasthenic syndrome resulting from <i>COL13A1</i> mutations. <i>Brain</i> , 2019, 142, 1547-1560.	7.6	30
16	Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. <i>Neuromuscular Disorders</i> , 2014, 24, 1036-1041.	0.6	29
17	Muscle magnetic resonance imaging in congenital myasthenic syndromes. <i>Muscle and Nerve</i> , 2016, 54, 211-219.	2.2	24
18	$\beta 2$ -Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure. <i>Brain</i> , 2019, 142, 3713-3727.	7.6	24

#	ARTICLE	IF	CITATIONS
19	Long-term Thalamic Deep Brain Stimulation for Essential Tremor: Clinical Outcome and Stimulation Parameters. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 567-572.	1.5	23
20	Labor asistencial del equipo de guardia de neurología en un hospital terciario de Madrid: análisis prospectivo durante un año. <i>Neurología</i> , 2014, 29, 193-199.	0.7	20
21	Paediatric myasthenia gravis: Prognostic factors for drug free remission. <i>Neuromuscular Disorders</i> , 2020, 30, 120-127.	0.6	18
22	Congenital myasthenic syndrome due to mutations in <i>MUSK</i> suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure. <i>Human Mutation</i> , 2020, 41, 619-631.	2.5	18
23	Hematoma espinal epidural espontáneo: estudio retrospectivo de una serie de 13 casos. <i>Neurología</i> , 2015, 30, 393-400.	0.7	13
24	SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	11
25	Congenital myasthenic syndrome due to a TOR1AIP1 mutation: a new disease pathway for impaired synaptic transmission. <i>Brain Communications</i> , 2020, 2, fcaa174.	3.3	11
26	Presynaptic congenital myasthenic syndrome due to three novel mutations in SLC5A7 encoding the sodium-dependant high-affinity choline transporter. <i>Neuromuscular Disorders</i> , 2021, 31, 21-28.	0.6	11
27	Acute hemocerebellitis in children: Case report and review of literature. <i>European Journal of Paediatric Neurology</i> , 2013, 17, 447-453.	1.6	10
28	Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody disease. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116881.	0.6	10
29	Myasthenic syndromes due to defects in COL13A1 and in the N-linked glycosylation pathway. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 163-169.	3.8	6
30	Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21228-21235.	7.1	4
31	Labor asistencial del equipo de guardia de neurología en un hospital terciario de Madrid: análisis prospectivo durante un año. <i>Contestación a Ráplica. Neurología</i> , 2016, 31, 578.	0.7	0
32	Labor asistencial del equipo de guardia de neurología en un hospital terciario de Madrid: análisis prospectivo durante un año. <i>Contestación a Ráplica. Neurología</i> , 2016, 31, 574-575.	0.7	0